Roquette marks new chapter at CPHI 2025 after key acquisitions

Roquette debuts its next chapter at CPHI 2025 following Qualicaps and IFF Pharma Solutions acquisitions

Showcasing the combined strength of Roquette’s Health & Pharma Solutions’ capabilities in excipients, capsules, APIs, and drug delivery technologies at booth 8.0P24 (hall 8) from October 28–30 in Frankfurt.

Lille, France, October 14, 2025 – At this year’s CPHI Frankfurt (booth 8.0P24, hall 8), Roquette will share its unified portfolio and strategic vision for the first time after having completed the acquisition of IFF Pharma Solutions. Together with the integration of Qualicaps, the newly formed Health & Pharma Solutions Business Group will present its expanded expertise ranging from consumer healthcare to prescription medications under the banner “United for Better Health,” providing an extensive portfolio in excipients, capsules, APIs, and drug delivery technologies as well as biopharmaceutical and nutraceutical solutions. Visitors are invited to join Roquette at its booth to discover how it is shaping the future of pharmaceutical innovation, drug development, and patient care.

Three legacies united for better health

Pharma Solutions in May 2025, this combined portfolio positions Roquette as a solutions-oriented partner for pharmaceutical, biopharmaceutical, and nutraceutical companies worldwide. With deep capabilities in technical excellence, polymer innovation, regulatory expertise, and sustainable manufacturing, it offers a comprehensive approach to formulation and development.

“This milestone marks the start of an exciting new chapter in our journey as an end-to-end global leader in pharmaceutical innovation,” said Isabelle Bouvier, CEO of the Roquette Health & Pharma Solutions Business Group. “By bringing together the strengths of three successful legacy businesses and over 75 years of expertise, we’ve expanded our ability to offer high-value drug delivery solutions that overcome modern pharma challenges. We provide excipients and APIs essential to life-saving therapies – making us the industry’s trusted partner for improving, sustaining, and ultimately saving lives. We’re excited to showcase our enhanced capabilities for the first time at CPHI Frankfurt and share how we can help create a healthier future for generations to come.”

Technology and innovation highlights 

At booth 8.0P24 (hall 8), Roquette will demonstrate how it goes beyond ingredients – bringing together newly integrated capabilities and technologies to advance drug delivery, compliance, and patient outcomes. 

Visitors will discover:

• Solutions for more effective, patient-friendly medicines – including Kleptose® HPBCD for solubility and taste masking; Pearlitol® mannitol for stabilizing sensitive APIs; METHOCEL™, ETHOCEL™, and POLYOX™ for controlled release; and Quali-V® HPMC capsules for moisture-sensitive formulations.
• Excipients and capsules designed to reduce nitrosamine risks and meet tightening global standards – such as Low Nitrite METHOCEL™ HPMC for controlled release with nitrosamine control, Avicel® LN MCC with a 100 ppb nitrite spec, and Pearlitol® Mannitol as a non-hygroscopic filler.
• Advanced coatings and capsule technologies for targeted release and process efficiencies – like ETHOCEL™ EC and Aquacoat® ECD barrier membrane coating, ReadiLycoat® plant-based coating systems, alginates for anti-reflux and pH-controlled release, and Quali-V®-I Capsules for optimal aerosolization in dry powder inhalation formulations.

Together, these solutions empower pharmaceutical developers to accelerate innovation and deliver high-performing therapies with confidence.

Visit Roquette at CPHI Frankfurt to discover how the combined strengths of three heritage organizations have created a powerhouse of expertise and value for the future of pharmaceutical advancement.

Media contacts

• Roquette Health & Pharma Solutions: Lisa Luke, Global Head of Communications, lisa.luke@roquette.com
• BDB: Oonagh Davies, roquettepharma@bdb.co.uk, +44 161 925 4700